Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB17170 drug-drug interaction study with midazolam in healthy volunteers
NCT06846684Phase 1Completed
- Sponsor
- SPARK Biopharma
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SB17170, sponsored by SPARK Biopharma. Primary endpoints: Maximum Plasma Concentration of SB_MDZ at Day 15 and Area Under the Plasma Concentration-Time Curve of SB_MDZ at Day 15. Started Mar 2025; status: completed.
02
Drugs
SB17170
Beyond the preview
Go deeper on NCT06846684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846684.